Lobbying

GE Healthcare Pharmaceutical Diagnostics's latest lobbying report covers Q1 2023, at $80K. Its first report covers Q4 2022; the issues it reports most are Health Issues.

GE Healthcare Pharmaceutical Diagnostics

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

GE Healthcare Pharmaceutical Diagnostics lobbying by quarter
GE Healthcare Pharmaceutical Diagnostics lobbying by quarter
QuarterAmountReports
Q4 2022$80K1
Q1 2023$80K1
Q2 2023$00
Q3 2023$00
Q4 2023$00
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$160K · 2 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES2 reports
  • SENATE2 reports

Firms it paid

Firm
King & Spalding$160K2 quarters

Former officials lobbying for it

Former position
SCOTT DZIENGELSKIRep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017)Q1 2023

Lobbying reports

Filed by
23/04/17for Q1 2023King & Spalding$80K
23/01/18for Q4 2022King & Spalding$80K